Twice‐daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin...

Por Franek, E., Haluzík, M., Canecki Varžić, S., Sargin, M., Macura, S., Zacho, J., Christiansen, J. S.
Publicado no Diabet Med (2015)

Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co‐formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomiz...

Por Rodbard, H. W., Cariou, B., Pieber, T. R., Endahl, L. A., Zacho, J., Cooper, J. G.
Publicado no Diabetes Obes Metab (2016)

Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double‐blind randomized controlled trial (...

Por Aroda, V. R., Bailey, T. S., Cariou, B., Kumar, S., Leiter, L. A., Raskin, P., Zacho, J., Andersen, T. H., Philis‐Tsimikas, A.
Publicado no Diabetes Obes Metab (2016)

Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis inv...

Por Simone, B, De Stefano, V, Leoncini, E, Zacho, J, Martinelli, I, Emmerich, J, Rossi, E, Folsom, AR, Almawi, WY, Scarabin, PY, den Heijer, M, Cushman, M, Penco, S, Vaya, A, Angchaisuksiri, P, Okumus, G, Gemmati, D, Cima, S, Akar, N, Oguzulgen, KI, Ducros, V, Lichy, C, Fernandez-Miranda, C, Szczeklik, A, Nieto, JA, Torres, JD, Le Cam-Duchez, V, Ivanov, P, Cantu, C, Shmeleva, VM, Stegnar, M, Ogunyemi, D, Eid, SS, Nicolotti, N, De Feo, E, Ricciardi, W, Boccia, S
Publicado em 2013